60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/N
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bleeding
Conditions
Bleeding
Trial Timeline
Oct 1, 2013 → May 1, 2014
NCT ID
NCT02047565About 60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/N
60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/N is a phase 1 stage product being developed by Daiichi Sankyo for Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT02047565. Target conditions include Bleeding.
What happened to similar drugs?
12 of 20 similar drugs in Bleeding were approved
Approved (12) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02047565 | Phase 1 | Completed |
Competing Products
20 competing products in Bleeding